Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alector Inc.
This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study.
All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks (q4w).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).
Has successfully completed participation in their parent latozinemab study.
Female participants must be nonpregnant and nonlactating.
Male participants must agree to acceptable contraception use.
You may not be if
Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.
Clareo Health | Continuation Study for Latozinemab
